Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions.

J Acquir Immune Defic Syndr. 2000 May 1;24(1):48-56. Unique Identifier : AIDSLINE MED/20334006
Chesson HW; Pinkerton SD; Division of STD Prevention, Centers for Disease Control and; Prevention, Atlanta, Georgia, USA.

Abstract: We estimated the annual number and cost of new HIV infections in the United States attributable to other sexually transmitted diseases (STDs). We used a mathematical model of HIV transmission to estimate the probability that a given STD infection would facilitate HIV transmission from an HIV-infected person to his or her partner and to calculate the number of HIV infections due to these facilitative effects. In 1996, an estimated 5,052 new HIV cases were attributable to the four STDs considered here: chlamydia (3,249 cases), syphilis (1,002 cases), gonorrhea (430 cases), and genital herpes (371 cases). These new HIV cases account for approximately $985 million U.S. in direct HIV treatment costs. The model suggested that syphilis is far more likely than the other STDs (on a per-case basis) to facilitate HIV transmission. This analysis provides a framework for incorporating STD-attributable HIV treatment costs into cost-effectiveness analyses of STD prevention programs.

Keywords: JOURNAL ARTICLE Chlamydia Infections/ECONOMICS/PREVENTION & CONTROL Communicable Disease Control/*ECONOMICS Cost-Benefit Analysis Female Gonorrhea/ECONOMICS/PREVENTION & CONTROL Herpes Genitalis/ECONOMICS/PREVENTION & CONTROL Human HIV Infections/*TRANSMISSION Male Mathematical Computing Probability Risk Factors Sexual Partners Sexually Transmitted Diseases/*ECONOMICS/*PREVENTION & CONTROL Support, U.S. Gov't, P.H.S. Syphilis/ECONOMICS/PREVENTION & CONTROL
001030
A00A1052

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .